However, your health care provider might consider alternatives such as Wegovy, Mounjaro, or Saxenda, all of which are GLP-1 medications but not all are FDA-approved for weight loss specifically.
Cardiovascular Protection A large clinical trial of 17,000+ adults with cardiovascular disease (but no diabetes) found that semaglutide reduced heart attacks, strokes, and cardiovascular death by 20%and those benefits began showing up before appreciable weight loss occurred
Like these companies, Oar Health provides an online platform allowing patients to receive medical evaluations and prescriptions without visiting a physical clinic or pharmacy
But that hasnt happened, and the companys CEO said on its Q2 earnings call that the copycat GLP-1 market is of equal size to Novos business-likely due to the lower cost of compounded drugs
Wilm B, et al
GLP-1s are no longer just for type-2 diabetes along with weight management